{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:06:42Z","timestamp":1793394402152,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.suronc.2026.102490","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:02:35Z","timestamp":1782802955000},"page":"102490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative safety of postoperative HIPEC with recombinant mutant TNF-\u03b1 versus paclitaxel for gastric cancer peritoneal metastasis: a randomized controlled trial"],"prefix":"10.1016","volume":"67","author":[{"given":"Zhao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaogang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6349-1618","authenticated-orcid":false,"given":"Chunwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.suronc.2026.102490_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejso.2022.08.023","article-title":"Clinical epidemiology of peritoneal metastases in China: the construction of professional peritoneal metastases treatment centers based on the prevalence rate","volume":"49","author":"Yang","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010117","article-title":"Emerging trends in the management of gastric malignancy with peritoneal dissemination: same disease, heterogeneous prognosis","volume":"17","author":"Mela","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.suronc.2026.102490_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70054","article-title":"Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis","volume":"14","author":"Peng","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"3","key":"10.1016\/j.suronc.2026.102490_bib5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.suronc.2026.102490_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/tgh.2020.02.08","article-title":"Molecular biology and immunology of gastric cancer peritoneal metastasis","volume":"5","author":"Yao","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.suronc.2026.102490_bib7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib8","first-page":"49","article-title":"The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future","volume":"73","author":"Foster","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21147\/j.issn.1000-9604.2023.01.03","article-title":"Intraperitoneal chemotherapy for gastric cancer: a contemporary perspective","volume":"35","author":"Kang","year":"2023","journal-title":"Chin. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.suronc.2026.102490_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.suronc.2014.03.004","article-title":"Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective","volume":"23","author":"Kitayama","year":"2014","journal-title":"Surg. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010100","article-title":"Evolution in the surgical management of gastric cancer peritoneal metastases","volume":"17","author":"Krell","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108790","article-title":"HIPEC for metastatic gastric cancer: moving the needle towards 3-year survival","volume":"51","author":"Bhutiani","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.suronc.2026.102490_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12029-024-01031-9","article-title":"Short-term safety evaluation of albumin-bound paclitaxel in intraoperative and postoperative hyperthermic intraperitoneal chemotherapy for gastric cancer","volume":"55","author":"Zhou","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12890-020-01210-x","article-title":"Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer","volume":"20","author":"Fu","year":"2020","journal-title":"BMC Pulm. Med."},{"issue":"48","key":"10.1016\/j.suronc.2026.102490_bib16","article-title":"A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers","volume":"101","author":"Wu","year":"2022","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820968900","article-title":"Predicting peritoneal metastasis of gastric cancer patients based on machine learning","volume":"27","author":"Zhou","year":"2020","journal-title":"Cancer Control"},{"key":"10.1016\/j.suronc.2026.102490_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/CEG.S482377","article-title":"Tumor-stroma ratio is a critical indicator of peritoneal metastasis in gastric cancer","volume":"18","author":"Zhong","year":"2025","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"4","key":"10.1016\/j.suronc.2026.102490_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.gassur.2003.12.014","article-title":"Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer","volume":"8","author":"Hall","year":"2004","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.suronc.2026.102490_bib20","first-page":"1328","article-title":"Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for the prevention and control of peritoneal metastasis in patients with gastrointestinal malignancies: a systematic review of randomized controlled trials","volume":"20","author":"Dominic","year":"2021","journal-title":"EXCLI J."},{"issue":"8","key":"10.1016\/j.suronc.2026.102490_bib21","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1097\/JS9.0000000000000457","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis","volume":"109","author":"Patel","year":"2023","journal-title":"Int. J. Surg."},{"issue":"23","key":"10.1016\/j.suronc.2026.102490_bib22","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2026.102490_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1245\/s10434-023-14415-1","article-title":"Gastrectomy + cytoreductive surgery + HIPEC for gastric cancer with peritoneal dissemination (PERISCOPE II)","volume":"31","author":"Sarvestani","year":"2024","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.suronc.2026.102490_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/jso.27877","article-title":"The effects of HIPEC on survival of gastric cancer patients with peritoneal metastasis","author":"Ji","year":"2024","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.suronc.2026.102490_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znag027","article-title":"Management of gastric cancer peritoneal metastasis: International gastric cancer association GCPM working group consensus statements","volume":"113","author":"Boshier","year":"2026","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.suronc.2026.102490_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2407-14-183","article-title":"GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study","volume":"14","author":"Glehen","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib28","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1186\/s12885-021-08872-8","article-title":"Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II\/III adenocarcinoma - the phase III \"PREVENT\"- (FLOT9) trial of the AIO\/CAOGI\/ACO","volume":"21","author":"G\u00f6tze","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.suronc.2026.102490_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020289","article-title":"Iterative intraperitoneal chemotherapy in gastric cancer peritoneal carcinomatosis","volume":"17","author":"Tajik","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.suronc.2026.102490_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"de Bree","year":"2017","journal-title":"Pleura Peritoneum"},{"issue":"2","key":"10.1016\/j.suronc.2026.102490_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.22.02644","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced Colon cancer (COLOPEC): 5-Year results of a randomized multicenter trial","volume":"42","author":"Zwanenburg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2026.102490_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2024.07.017","article-title":"Intraperitoneal drug delivery systems for peritoneal carcinomatosis: bridging the gap between research and clinical implementation","volume":"373","author":"Perell\u00f3-Trias","year":"2024","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010376","article-title":"TNF-\u03b1 secreted from macrophages increases the expression of prometastatic integrin \u03b1V in gastric cancer","volume":"24","author":"Hwang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.suronc.2026.102490_bib34","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s41388-019-1078-x","article-title":"The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-\u03b1\/IL-33\/ST2L signaling promotes gastric cancer metastasis","volume":"39","author":"Zhou","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.suronc.2026.102490_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/1535370220905047","article-title":"Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-\u03b1 and raltitrexed in mice with colorectal-peritoneal carcinomatosis","volume":"245","author":"Gong","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"10.1016\/j.suronc.2026.102490_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.soc.2012.07.013","article-title":"Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy","volume":"21","author":"Van der Speeten","year":"2012","journal-title":"Surg. Oncol. Clin."},{"issue":"1","key":"10.1016\/j.suronc.2026.102490_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann. Oncol."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740426001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740426001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:34:01Z","timestamp":1791747241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740426001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0960740426001416"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2026.102490","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of postoperative HIPEC with recombinant mutant TNF-\u03b1 versus paclitaxel for gastric cancer peritoneal metastasis: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2026.102490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102490"}}